GT Medical Technologies has closed an oversubscribed $100 million Series E financing to support the growth of its GammaTile radiation therapy device, designed for patients undergoing brain tumor removal surgery.
Led by Viking Global Investors, the round included participation from existing investors and follows a $53 million Series D financing completed last year.
Related: CeQur closes $100M Series E to support mealtime insulin patch
GammaTile delivers immediate, targeted radiation during surgery, eliminating the delay often required before traditional radiation therapy begins. The company says this approach may improve treatment effectiveness and reduce the risk of tumor regrowth.
The funding will support commercial expansion, operational growth, and clinical development, including the ongoing BRIDGES trial for newly diagnosed glioblastoma patients.
GT Medical CEO Per Langoe said:
“This financing is validation of GammaTile’s potential to be a standard of care treatment for operable brain tumors and will accelerate our ability to bring this important therapy to even more patients.”
